Here, in the intratibial LNCaP xenograft model, the combination of radium-223 and enzalutamide resulted in decreased serum PSA levels and areas of tumor-induced abnormal bone, while either radium-223 or enzalutamide alone did not decrease serum PSA. Here, KLK3 is linked to neoplasm.